Lenvatinib plus Pembrolizumab following immune checkpoint inhibitor treatment in patients with metastatic clear cell renal cell carcinoma: Results from study 111/KEYNOTE-146 Research Letter

  

Authors:	Lee, C. H.; Yogesh Shah, A.; Rao, A.; Taylor, M. H.; Di Simone, C.; Hsieh, J. J.; Pinto, A.; Gironés Sarrió, R.; Lee Cohn, A.; Asim Bilen, M.; Gunnestad Ribe, S.; Krohn Tennøe, Ø; Richards, D.; Sweis, R. F.; Courtright, J.; Heinrich, D.; Perini, R.; Kubiak, P.; Bock, D.; Okpara, C. E.; Motzer, R. J.
Title:	Lenvatinib plus Pembrolizumab following immune checkpoint inhibitor treatment in patients with metastatic clear cell renal cell carcinoma: Results from study 111/KEYNOTE-146
Keywords:	adult; cancer survival; major clinical study; overall survival; drug safety; cancer patient; letter; progression free survival; drug combination; metastatic renal cell carcinoma; immune checkpoint inhibitor; lenvatinib; human; female; pembrolizumab; checkpoint inhibitor therapy
Journal Title:	European Urology
Volume:	86
Issue:	5
ISSN:	0302-2838
Publisher:	Elsevier Science, Inc.
Date Published:	2024-11-01
Start Page:	470
End Page:	473
Language:	English
DOI:	10.1016/j.eururo.2024.05.003
PUBMED:	38777648
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85195379902&doi=10.1016%2fj.eururo.2024.05.003&partnerID=40&md5=56a5634696ef2a96bb292a9a8a92b324
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF. Corresponding MSK author is Robert J. Motzer -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/220694